Astrazeneca Pharma India Ltd Share Price Today - Astrazeneca Pharma India Ltd Stock Price Live NSE/BSE

Astrazeneca Pharma India Ltd

NSE: ASTRAZEN BSE: 506820

₹8760

(-0.63%)

Sat, 14 Mar 2026, 09:59 am

MTF 5xInvest in Astrazeneca Pharma India Ltd with 5x Leverage Buy with MTF

Market Cap220.04B

PE Ratio109.01

Dividend0.37

Health Technology

Pharmaceuticals: Major

24.5K

Astrazeneca Pharma India Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
20974.63
Net Profit
115.74
P/B
27.93
Sector P/E
40.97
P/E
185.88
EV/EBITDA
106.24
Debt/Equity (Industry)
0.09
Interest Cover (Industry)
38.34
ROCE (Industry)
22.21
RONW (Industry)
17.92
ROE
23.63
ROCE
32.94
Debt/Equity
0.03
EPS (TTM)
83.21
Dividend Yield
0.38
Book Value
319.60
Interest Cover
174.17

Analysis

all

Pros

AstraZeneca Pharma India is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
AstraZeneca Pharma India is profitable, therefore cash runway is not a concern.
AstraZeneca Pharma India is profitable, therefore cash runway is not a concern.
AstraZeneca Pharma India has no debt, it does not need to be covered by operating cash flow.
AstraZeneca Pharma India has no debt, it does not need to be covered by short term assets.

Cons

AstraZeneca Pharma India is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
No need to calculate the sustainability of AstraZeneca Pharma India's dividends as it is not paying a notable one for India.
AstraZeneca Pharma India is not paying a notable dividend for India, therefore no need to check if the payments are stable.
AstraZeneca Pharma India's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
AstraZeneca Pharma India's dividend is below the markets top 25% of dividend payers in India (3.08%).

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	75	75	75	75	75
FII	2.71	2.74	3.03	2.89	2.93
DII	5.56	5.26	4.56	4.65	5.22
Public	16.73	17.00	17.41	17.46	16.85
Government	0	0	0	0	0

Technical Analysis

RSI

35.69

MACD

-31.38

50 DMA

8614.58

200 DMA

8965.64

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	10412.17	9622.67	9235.83	8833.17	8446.33	8043.67	7254.17
Fibonacci	9622.67	9321.08	9134.76	8833.17	8531.58	8345.26	8043.67
Camarilla	9066.11	8993.74	8921.37	8833.17	8776.63	8704.26	8631.89

Pivots Level: Classic

+1579

10412.17

+789.50

9622.67

+402.67

9235.83

8833.17

Pivot Point

LTP: 8401

-386.83

8446.33

-789.50

8043.67

-1579

7254.17

Moving Average

SMAEMA

Period

Value

10-EMA
8671.63
20-EMA
8714.32
30-EMA
8720.58
50-EMA
8739.98
100-EMA
8791.41
200-EMA
8670.26

Announcement Date	Purpose	Action	Ex Date
11 Feb 2026	board-meetings	Quarterly Results
07 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
28 Jul 2025	agm
18 Jun 2025	dividend	Dividend - Rs. - 32	18 Jul 2025
30 May 2025	dividend	₹32.00 Dividend /Share	18 Jul 2025
16 Jul 2024	agm
05 Jun 2024	dividend	Final Dividend - Rs. - 24	05 Jul 2024
27 May 2024	dividend	₹24.00 Dividend /Share	05 Jul 2024
22 Jul 2023	agm
14 Jun 2023	dividend	Dividend - Rs. - 16	14 Jul 2023

Astrazeneca Pharma India Ltd

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Cipla Ltd

Divis Laboratories Ltd

Astrazeneca Pharma India Ltd About

Astrazeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinicaltrial services to an overseas group company.(Source : 202503-Annual Report Page No:148)

Industry

Pharmaceuticals - Multinational

Founded

1979

Headquarters

CEO

Shilpa Divekar Nirula

Employees

Contact

Website

http://www.astrazeneca.in

comp.secy@astrazeneca.com

Phone

91-080-67748000

Location

Blk N1 12th Flr Manyata Embass, Rachenahalli Outer Ring Road, Bangalore, Karnataka, 560045

Year	History
2018	AstraZeneca Pharma India Ltd receives DCGI permission for Durvalumab.
2021	AstraZeneca partners with DocOn to digitize healthcare clinics across India. AstraZeneca and Rajiv Gandhi Cancer Institute launch Project Chariot for CLL diagnosis and treatment. AstraZeneca launches Clinical Data and Insights division in India.
2022	AstraZeneca Pharma receives CDSCO approval for Dapagliflozin tablets.
2023	AstraZeneca inaugurates Centre of Excellence at Manipal Hospital Goa for severe asthma patients. AstraZeneca India partners with Roche Diagnostics India to improve breast cancer diagnostic testing. Government of Karnataka signs MoU with AstraZeneca India to accelerate lung cancer testing.
2024	AstraZeneca Pharma India Ltd and Mankind Pharma Ltd announce collaboration for exclusive distribution of Symbicort in India. AstraZeneca India receives CDSCO approval for Durvalumab additional indication. AstraZeneca and Vaayu Chest & Sleep Center collaborate to enhance respiratory care for severe asthma patients in Bengaluru. AstraZeneca receives CDSCO approval to import and market Andexanet Alfa for critical bleeding conditions.

Client Name	Order Side	QTY	Avg Price	Date
GRAVITON RESEARCH CAPITAL LLP	Buy	125166	7884.41	07 Oct 2024
GRAVITON RESEARCH CAPITAL LLP	Sell	125166	7887.16	07 Oct 2024
GRAVITON RESEARCH CAPITAL LLP	Buy	127119	7802	30 Sept 2024
GRAVITON RESEARCH CAPITAL LLP	Sell	127119	7804.96	30 Sept 2024
GRAVITON RESEARCH CAPITAL LLP	Buy	131308	7499.17	24 Sept 2024
GRAVITON RESEARCH CAPITAL LLP	Sell	131308	7506.36	24 Sept 2024
ICICI PRUDENTIAL MUTUAL FUND A/C VOLATILITY ADVANTAGE PLAN	Sell	125000	2000	03 Apr 2019
CROSSEAS CAPITAL SERVICES PVT. LTD.	Buy	131291	844.46	30 May 2013
CROSSEAS CAPITAL SERVICES PVT. LTD.	Sell	128849	845.78	30 May 2013
CROSSEAS CAPITAL SERVICES PRIVATE LIMITED	Sell	126180	845.63	30 May 2013

Astrazeneca Pharma India Ltd News

AstraZeneca Pharma Files SEBI Compliance Certificate

AstraZeneca Pharma India submitted regulatory compliance certificate to stock exchanges confirming adherence to SEBI dematerialization regulations for February 2026 period.

13 Mar 2026

companies

AstraZeneca Pharma Appoints New Director - Legal

AstraZeneca Pharma India Limited has appointed Mrs. Sandhya Tejaswini Amanna as Director - Legal, effective March 18, 2026. She brings over two decades of experience in manufacturing, FMCG, and pharmaceutical sectors.

11 Mar 2026

stocks

AstraZeneca Pharma India Seeks Approval for ₹3,900 Cr RPTs

AstraZeneca Pharma India Limited announces postal ballot for shareholder approval of material related party transactions worth ₹3,900 crore with UK and Swedish entities for FY27.

27 Feb 2026

co actions results

AstraZeneca Gets CDSCO Nod for Imfinzi Cancer Drug

AstraZeneca Pharma India receives regulatory approval to import and distribute Durvalumab Solution (Imfinzi) for treating advanced endometrial cancer in combination therapy.

10 Feb 2026

stocks

AstraZeneca Gets CDSCO Nod for Durvalumab Cancer Drug

AstraZeneca Pharma India receives regulatory approval for additional indication of Durvalumab (Imfinzi) to treat gastric and gastroesophageal junction adenocarcinoma in adult patients.

31 Jan 2026

stocks

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800